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Opinion statement
Anaplastic oligodendroglial tumors have gained increasing interest with the emerging
role of molecular markers and systemic chemotherapy during the past years. The long-
term results of two landmark trials, RTOG 9402 and EORTC 26961, have resulted in a
reconsideration of the appropriate therapeutic approaches for patients with these tu-
mors. Both trials indicate that patients whose tumors harbor a 1p/19q co-deletion ben-
efit particularly from the addition of procarbazine/lomustine (CCNU)/vincristine (PCV)
chemotherapy to radiation therapy (RT). The median survival of patients with co-delet-
ed tumors treated within the RTOG trial with PCV before irradiation was 14.7 years com-
pared with 7.3 years of patients who received RT alone. Median overall survival has not
been reached in the RT plus PCV arm of the EORTC trial, but a similar difference can be
anticipated after a follow-up of more than 12 years. In contrast, no such benefit was
observed for patients with tumors lacking 1p/19q co-deletion. Outside clinical trials,
patients with anaplastic oligodendroglial tumors, and 1p/19q co-deletion therefore
should be offered a combined treatment modality regimen, including radio- and che-
motherapy. PCV, however, is associated with significant hematological toxicity and al-
so nonhematological side effects, which probably translate into reduced quality of life
for long-term survivors. Therefore, it might be warranted to replace PCV by
temozolomide, which displays a more favorable side effect profile. Data from the
NOA-04 study suggest that PCV and temozolomide have similar effects. However,
long-term data on the benefit from temozolomide are lacking, making a definite an-
swer on the equivalence of temozolomide and PCV in anaplastic oligodendroglioma
(AO) impossible. The current evidence precludes RT alone for AO patients. Neither
the RTOG nor the EORTC trial defined the role of chemotherapy alone. A comparison of
combined modality treatment with chemotherapy alone followed by RT at progression
is pending. Long-term follow-up of NOA-04 patients and results from future trials may
help to clarify these questions. With more and more AO patients living 10 years or
more, particular attention must be paid to late side effects, such as neurotoxicity,
and careful monitoring is required for all treated patients.
Introduction
The group of anaplastic gliomas, also referred to asWorld
Health Organization (WHO) grade III tumors, has been
histologically subdivided into different subtypes: ana-
plastic astrocytoma (AA), anaplastic oligoastrocytoma
(AOA), anaplastic oligodendroglioma (AO), and ana-
plastic ependymoma [1]. Anaplastic oligodendroglial tu-
mors are rare, accounting for less than 5 % of all primary
brain tumors (cbtrus.org). In contrast toWHOgrade II tu-
mors, these neoplasms display histological features of an-
aplasia, such as nuclear atypia, as well as enhanced
cellularity and increased number of mitotic figures. The
MIB1 index as a marker for proliferation is typically
higher than 5%. The current WHO classification for glio-
mas lacks the inclusion ofmolecularmarkers, which have
gained increasing interest within the past years and have
been proven to be of prognostic significance [2•, 3]. This
is of particular interest in anaplastic but also WHO grade
II gliomas where the interobserver variability in the sub-
jective interpretation of the histopathological findings is
still significant [4]. Oligodendroglial tumors are charac-
terized by the frequent loss of genetic material from the
short arm of chromosome 1 (1p) and the long arm of
chromosome 19 (19q) [5]. This situation, also referred
to as combined 1p/19q loss or 1p/19q co-deletion, is
due to an unbalanced translocation resulting in the loss
of one hybrid chromosome and loss of heterozygosity
(LOH) [6]. How these chromosomal aberrations contrib-
ute to the pathogenesis of oligodendroglial tumors has
not yet been clarified, butmutations of different genes, in-
cluding homolog of the Drosophila gene capicua (CIC) and
far-upstream element (FUSE) binding protein (FUBP1), lo-
catedon these chromosomal fragmentsmayplay a critical
role [7••]. In the absence of radiation therapy or
alkylating chemotherapy, 1p/19q co-deletion may not
be associated with prolonged progression-free survival
[8], indicating that it is not a prognostic biomarker but
rather a predictor for favorable responses to radio- or che-
motherapy.
Treatment
The therapeutic management of AO requires a multidisciplinary approach,
including surgery, irradiation, and chemotherapy. The importance of
alkylating chemotherapy has been confirmed recently by the long-term re-
sults of two randomized, phase III trials. However, it remains a matter of de-
bate whether irradiation can be deferred and which alkylating chemotherapy
regimen is most suitable in terms of efficacy and toxicity.
Surgery
& Even with RT and improved chemotherapeutic options (see below),
surgery has remained the initial therapeutic procedure. Resection allows
for rapid relief from intracranial pressure andneurological symptoms in
tumors that are associated with a significant mass effect.
& There is no clear evidence on the beneficial effects of a gross total
506 Neuro-oncology (GJ Lesser, Section Editor)
resection in anaplastic oligodendroglial tumors. However, based on
the results of several studies that assess mainly glioblastoma patients,
it may be concluded that complete resection also is favorable for the
outcome with anaplastic gliomas. 5-aminolevulinic acid (5-ALA) is
used for the intraoperative identification and resection of gliomas.
Compared with conventional microsurgery, 5-ALA-based resection
resulted in more complete resections of contrast-enhancing tumor,
which translated into prolonged progression-free survival [9]. Similar
to many other trials, including patients with WHO grade III and IV
gliomas, the majority of patients treated within this study had a
histological diagnosis of glioblastoma. Only 3 % of the operated
tumors were finally diagnosed as anaplastic oligodendroglial glio-
mas. Therefore, the role of 5-ALA for the resection of AO remains
questionable.
& Most meta-analyses addressing the effect of surgical resection versus
biopsy include various histological types of malignant gliomas.
Overall, resection may improve the quality of life and also increase
overall survival [10]. In parallel, surgery-associated mortality has
decreased most likely due to the availability of advanced
intraoperative imaging techniques and improved perioperative
neuro-anesthesiological care.
& The extent of resection should be confirmed by an appropriate im-
aging technique, typically MRI, not later than 72 h after the opera-
tion. Extent of resection has been identified as a prognostic factor in
several large clinical trials [11, 12, 13••].
& Because of the increasing importance of molecular markers, the
availability of tissue specimens is crucial and represents another
important aspect of surgery. Patients whose tumors are not eligible
for complete resection due to the localization in the brain or other
reasons need to undergo a biopsy for tissue sampling to allow for
subsequent histological and molecular profiling.
Radiation therapy
& Surgery followed by irradiation was the standard of care of anaplastic
oligodendroglioma until the early 1990s. Only trials performed
during the 1970s examined the effect of radiotherapy alone in pa-
tients with malignant gliomas. Histological glioma specification,
however, was mostly lacking at that time resulting in a mixture of
grade III and IV tumors [14].
& Randomized trials enrolling specifically patients with AO looking at
the net effect of irradiation compared to surgery alone have not been
performed and probably will never. Still, there is hardly any doubt
that radiotherapy is an effective treatment for patients with AO. This
assumption is stressed by retrospective analyses of patient cohorts
who had postoperative RT or not reporting that irradiation
prolonged survival [15].
& External beam RT is usually administered in standard fractions of
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1.8-2 Gy to a total dose in the range of 54 to 60 Gy. There are no data
to suggest a beneficial effect of doses higher than 60 Gy [16]. Fur-
thermore, whole brain irradiation (WBRT) is not more effective than
partial brain treatment. Clinical trials looking specifically at patients
with AO are lacking. In contrast to WBRT, focused radiotherapy may
be better tolerated and results much less frequently in reduced
quality of life [17].
Chemotherapy
& For many years, there was no consensus about the value of adjuvant
chemotherapy in patients with anaplastic gliomas. However, it has
been recognized more than 25 years ago that anaplastic oligoden-
droglial tumors are markedly more sensitive to chemotherapy than
most other gliomas [18]. Several smaller, uncontrolled trials within
the 1990s reported that AO frequently respond to chemotherapy
[19]. The most commonly administered regimen within these studies
included procarbazine, lomustine (CCNU), and vincristin (PCV).
& The observation that anaplastic oligodendroglial tumors respond
well to PCV chemotherapy resulted in the design of two similar trials
by the Radiation Therapy Oncology Group (RTOG) and the Euro-
pean Organisation for Research and Treatment of Cancer (EORTC).
Both studies evaluated the role of PCV chemotherapy in combina-
tion with radiotherapy compared with radiation therapy alone. The
RTOG 9402 trial randomly assigned 291 patients with AO or ana-
plastic mixed oligo-astrocytoma to either RT alone or up to four
cycles of PCV chemotherapy with subsequent RT [11]. The EORTC
26951 study enrolled 368 patients with pure or mixed anaplastic
oligodendrogliomas and randomized them to receive either RT alone
or RT followed by up to six cycles of PCV [12].
& Initial results of both studies were published in 2006 after a median
follow-up period of 5 years. Both trials had similar outcomes: (i)
patients with 1p/19q co-deletion had a longer median survival than
patients with non co-deleted tumors; (ii) progression-free survival
(PFS) time favored the combination of RT and PCV in both studies;
(iii) median overall survival (OS) was not different between the RT
only and the combined modality treatment groups, that is, regardless
of whether PCV was given before or after RT; and (iv) the addition of
PCV to irradiation was associated with significant, mostly hemato-
logical toxicity.
& Because of the lack of benefit on overall survival and the consider-
able toxicity, the addition of PCV to RT was not established as a new
standard of care. Of note, most of the patients who experienced tu-
mor progression after sole irradiation received chemotherapy as sal-
vage treatment in both trials. It was believed that this crossover effect
from chemotherapy that was applied at progression precluded the
translation of prolonged PFS into a difference in OS.
& In 2013, long-term follow-up data from both trials were reported
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[20••, 21••]. The long-term results of these two trials have now
changed the standards of care for patients with pure and mixed ana-
plastic oligodendroglial tumors. In the RTOG study, there was no dif-
ference inmedian survival when the entire patient cohort was analyzed.
However, within the subgroup of patients with co-deleted tumors, PCV
plus RT resulted in amedian survival of 14.7months vs. 7.3months for
those who had been treated with RT alone. No difference in median
survival was observed for patients with non co-deleted tumors. Long-
term results of the EORTC trial were obtained after a median follow-up
of 140 months. In contrast to the RTOG trial, there was a prolonged
median survival when the whole cohort was assessed, regardless of the
1p/19q status (OSwith RT/PCV42.3months vs. 30.6months, p=0.18).
Eighty patients had a 1p/19q co-deletion. Here, OS was not yet reached
in the RT/PCVgroup vs. 112months in theRT group. In the subgroupof
patients with non co-deleted tumors, no significant difference between
the RT and RT/PCV arm was observed.
& Because both trials used different approaches for the sequencing of
radio- and chemotherapy, both options are valid. Consideration may
be given to the influence of pre-radiotherapeutic chemotherapy in
responding patients on the target volume. However, as of now, the
target volume will be based on the initial postsurgical MRI.
& PCV administration results in considerable side effects with hemato-
logical toxicity as the major limitation. Grade 3 or 4 hematological
toxicity was observed in 47% of the patients treated within the EORTC
trial [12] and in 65 % of all patients who were enrolled in RTOG 9402
[11]. Only 42% of the patients treated within RTOG 9402 tolerated all
four cycles of PCV. Similarly, in EORTC 26951, a median of three of six
planned cycles of adjuvant PCV was administered. Only 30 % of the
patients could receive all scheduled six PCV cycles. Nevertheless, despite
many patients not receiving the planned chemotherapeutic regimen,
the combined treatment modality arm of the study resulted in superior
survival as demonstrated by the long-term follow-up.
& Because 1p/19q co-deletion is more predictive for the clinical course
than histology, two large randomized, multicenter trials have been
set up for patients with anaplastic glioma using the 1p/19q status as
inclusion criterion. The CATNON (NCT00626990) study has been
established for patients with tumors lacking a 1p/19q co-deletion.
This trial is currently enrolling patients. However, based on the recent
findings of RTOG 9402 and EORTC 26951, the second intergroup
study, named CODEL (NCT00887146), which had been designed
for patients with anaplastic gliomas harboring a 1p/19q co-deletion,
was put on hold. The trial had been set up with three arms com-
paring RT plus concomitant and adjuvant TMZ with RT alone or TMZ
alone. After publication of the long-term results of the RTOG and
EORTC studies, the irradiation only arm was no longer regarded
appropriate. Whether this trial will be continued following design
modifications is still a matter of debate. The trial may be resumed
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following a replacement of the RT only arm by a regimen that in-
cludes RT plus PCV.
& A major unresolved question is whether RT can be deferred in favor
of chemotherapy alone in patients with co-deleted tumors. Whether
PCV or temozolomide should be used is another matter of debate.
Currently, no data from large, prospective trials are available.
Therefore, the results of ongoing and future trials need to be awaited.
& The use of PCV had been abandoned by many neuro-oncologists
within the last decade because of its significant, mostly hematolog-
ical toxicity as outlined above. A survey demonstrated that 42 % of
neuro-oncologists use temozolomide alone in patients with AO
harboring a co-deletion, whereas only 8 % use PCV [22]. A similar
analysis revealed that the PCV regimen was virtually completely re-
placed by temozolomide among patients with AO who received
chemotherapy alone or together with RT [23].
& There also is a debate on the role of vincristine within the PCV reg-
imen. Most likely, it does not cross the blood–brain barrier and
therefore may lack activity against gliomas. In contrast, it may exert
severe and nonreversible side effects, such as neuropathies hamper-
ing the quality of life of many patients [24–26]. On the other hand,
we do not know which drug levels in the contrast-enhancing tumor
parts may be of benefit for tumor treatment, and the EORTC and
RTOG data have been achieved with PCV and not PC.
Temozolomide, when administered concomitantly during RT and as
adjuvant treatment in patients with newly diagnosed glioblastoma,
had only to be stopped in 13 % of the patients indicating that such a
regimen is much better tolerable than PCV [27]. Furthermore, in
contrast to PCV where vincristine requires intravenous application,
temozolomide can be administered orally, making it a very conve-
nient therapeutic option. Temozolomide, when used in AO patients
at relapse after failure of PCV resulted in considerable response rates
and promising survival data [28, 29]. More recent studies applied
temozolomide alone in patients with newly diagnosed AO,
suggesting similar activity than PCV [30]. In contrast, a retrospective
analysis assessing the effects of PCV and temozolomide in patients
with AO demonstrated prolonged survival of patients treated with
PCV with a median survival of 7.6 years compared with 3.3 years in
patients who received temozolomide [31•]. However, because of the
retrospective design of the study, these results may be biased by
several confounding factors. Overall, there is no similar evidence for
the activity of temozolomide in AO compared with PCV.
& The long-term results of the NOA-04 study may partially help to
clarify the issue of PCV vs. temozolomide chemotherapy as well as
the option of deferred RT. The study assessed efficacy and safety of RT
or chemotherapy with either PCV or temozolomide in patients with
anaplastic gliomas. At tumor progression, patients within the RT arm
were treated with chemotherapy and patients who were initially
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treated with PCV or temozolomide received RT as salvage treatment.
The trial revealed that both initial radio- and chemotherapy resulted
in similar median PFS and OS [13]. Patients with pure and mixed
anaplastic oligodendroglial tumors had virtually the same outcome.
Prognostic factors confirmed and identified within this trial included
age, extent of resection, histology, MGMT promoter methylation
status, and IDH1 mutation status. The study also confirmed the
much better tolerability of temozolomide. Whether first-line che-
motherapy alone results in promising OS times similar to the com-
bination of RT and PCV in RTOG 9402 and EORTC 26951 will only
be clarified by a long-term follow-up. Because only a minority of
patients treated within the NOA-04 trial had co-deleted tumors, it
must be anticipated that further trials are needed for a definitive
answer to this question.
Other treatments
& Except for surgery, irradiation and chemotherapy using PCV or
temozolomide, no further treatment modalities have been
established in patients with AO. Whenever possible, new phar-
maceutical agents as well as novel therapeutic approaches, such as
immunotherapy or gene therapy should be assessed within clinical
trials.
& Anti-angiogenic compounds, such as the vascular endothelial growth
factor (VEGF) inhibitor bevacizumab, have shown some activity in
glioblastoma patients [32]. Several smaller studies using
bevacizumab alone or in combination with other agents in patients
with recurrent oligodendroglial tumors suggest that bevacizumab
also is active in these tumors [33, 34•, 35, 36]. However, the definite
role of bevacizumab and similar compounds for the treatment of
oligodendroglial tumors—just as for all other grade II and III
tumors—needs to be defined within the next years. The TAVAREC
trial (NCT01164189), which is currently enrolling patients with re-
current anaplastic gliomas without 1p/19q co-deletion, may shed
some light on the efficacy of bevacizumab in these tumors.
Diet and lifestyle
& Currently, no data suggest that diet and lifestyle changes may have
any impact on the course of disease in AO patients.
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